Nasdaq

Voyager Provides Update on SOD1 ALS Gene Therapy Program

LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to ...
Nasdaq

Clene to Provide CNM-Au8® ALS Program Update

SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage ...
FierceBiotech

Metagenomi axes ALS program after seeing Biogen and Ionis flounder

Metagenomi is editing its pipeline, choosing to seek a partner for a program Moderna dropped and axing its amyotrophic lateral sclerosis (ALS) activities in response to setbacks at a competitor. The ...
STAT

My stalled relay race to get access to ALS drugs in development

One night in November 2018, I fell while crossing a street in Subic Bay, a U.S. naval logistics station in The Philippines. My face whacked the asphalt. Lying in the path of oncoming traffic, I couldn ...
Business Wire

Team Gleason Donates $750,000 To Expand Boston Children’s Hospital’s ALS Augmentative Communication Program. This Five-year Collaboration Will Provide Services to People ...

NEW ORLEANS & BOSTON--(BUSINESS WIRE)--Team Gleason, a leading foundation for ALS patient support, is collaborating with Boston Children’s Hospital’s ALS Augmentative Communication Program, which ...